Resumo:
En
|
Texto:
En
|
PDF:
En
ABSTRACT Background: This study aimed to evaluate the effectiveness and safety of direct-acting antivirals (DAAs) for hepatitis C treatment by measuring sustained virologic response (SVR) and serious adverse events to help design effective interventions for reducing disease prevalence. Methods: This was a retrospective, observational, real-life study of patients with chronic hepatitis C receiving DAA treatment in the state of Ceará, Brazil. Data were collected in REDCap and analyzed using R® software by the Student's t, chi-square, and Fisher’s exact tests, with a significance level of 5%. Results: In this study, 1075 patients who were diagnosed with hepatitis C infection between October 2015 and October 2023 were included. The mean age of the participants was 56.6 ± 11 years and 60.2% were men. The sample included 51 HIV-infected patients (6.6%), 166 (15,4%) liver transplant recipients, 34 (3,1%) kidney transplant recipients, and 446 patients with cirrhosis (41.4%). The overall SVR rate was 96.4%. The sofosbuvir/daclatasvir/ribavirin regimen used in 354 (32.9%) patients achieved an SVR of 96%. The cure rate was 96.5%, with a lower SVR in patients with cirrhosis (93.4%) than in those with less severe fibrosis (97.9%) (p=0.0015). Serious adverse events associated with ribavirin use occurred in 3.5% of patients. Conclusions: DAA treatment for hepatitis C achieved SVR in real life in all patient profiles, including transplant recipients, HIV carriers, and patients with cirrhosis. Although these drugs are safe, a few decompensated patients with cirrhosis died during treatment. Background directacting direct acting DAAs (DAAs (SVR prevalence Methods retrospective observational reallife Ceará Brazil R Students Student s t chisquare, chisquare chi square, square chi-square Fishers Fisher tests 5 5% Results 107 201 202 566 56 6 56. 1 602 60 2 60.2 men HIVinfected infected 6.6%, 66 6.6% , (6.6%) 16 15,4% 154 15 4 (15,4% recipients 3 3,1% 31 (3,1% 44 41.4%. 414 41.4% . 41 (41.4%) 964 96 96.4% sofosbuvirdaclatasvirribavirin sofosbuvir daclatasvir 35 32.9% 329 32 9 (32.9% 96% 965 96.5% 93.4% 934 93 (93.4% 97.9% 979 97 (97.9% p=0.0015. p00015 p p=0.0015 0 0015 (p=0.0015) 3.5 Conclusions profiles carriers safe 10 20 60. 6.6 (6.6% 15,4 (15,4 3,1 (3,1 41.4 (41.4% 96.4 32.9 (32.9 96.5 93.4 (93.4 97.9 (97.9 p0001 p=0.001 001 (p=0.0015 3. 6. (6.6 15, (15, 3, (3, 41. (41.4 96. 32. (32. 93. (93. 97. (97. p000 p=0.00 00 (p=0.001 (6. (15 (3 (41. (32 (93 (97 p00 p=0.0 (p=0.00 (6 (1 ( (41 (9 p0 p=0. (p=0.0 (4 p=0 (p=0. p= (p=0 (p= (p